Feb 09 2024
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in 2024

Posted at Feb 09 2024
h in News by Cara Weaver

OSAKA, Japan, and CAMBRIDGE, Massachusetts, February 8, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a randomized, double-blind, placebo-controlled, multiple dose Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients with narcolepsy type 1.

Read full statement here.

Print page

Feb 09 2024 Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in 2024

2 events, 29

2 events, 29

2 events, 30

2 events, 30

2 events, 1

2 events, 1

1 event, 2

1 event, 2

1 event, 3

1 event, 3

1 event, 4

1 event, 4

0 events, 5

0 events, 5

2 events, 6

2 events, 6

2 events, 7

2 events, 7

2 events, 8

2 events, 8

2 events, 9

2 events, 9

1 event, 10

1 event, 10

1 event, 11

1 event, 11

0 events, 12

0 events, 12

2 events, 13

2 events, 13

2 events, 14

2 events, 14

2 events, 15

2 events, 15

1 event, 16

1 event, 16

1 event, 17

1 event, 17

1 event, 18

1 event, 18

0 events, 19

0 events, 19

2 events, 20

2 events, 20

2 events, 21

2 events, 21

2 events, 22

2 events, 22

1 event, 23

1 event, 23

1 event, 24

1 event, 24

1 event, 25

1 event, 25

0 events, 26

0 events, 26

2 events, 27

2 events, 27

Feb 09 2024
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in 2024